It said higher demand for bestselling asthma and eczema drug Dupixent would be offset by increasing competition for its multiple sclerosis pill Aubagio.

It said the tablet, with over $2 billion in sales last year, will face rival cheaper products after after losing patent protection.

The French drugmaker said it expected 2023 earnings per share to grow by a "low single digit" percentage.

Sanofi's fourth-quarter operating income jumped over 20% to around $3 billion, edging past analyst estimates.

The company reaffirmed its Dupixent sales target of around $11 billion this year, up more than a fifth from 2022.

The drugmaker is also seeking to widen the pill's use across more conditions, with investors waiting on trials with smokers and lung disease sufferers.

Sanofi shares fell 3% in early Friday trade, following the firm's cautious outlook.